Insulins (Non-Long Acting Products)
Customize your policy alerts
Sign up for blue cross blue shield - louisiana Policy 00395 alerts
Get alerted when Policy 00395 changes without checking for updates manually.
Monitor payer policy activity
Coverage eligibility for non-long-acting insulin products outside the Novolin, Kirsty (insulin aspart-xjhz), and Insulin Lispro Authorized Branded Generic families, subject to the member contract.
Afrezza was added to the insulin policy.
Fiasp was added to the first-line products.
Admelog was added to the policy.
The insulin lispro branded generic was added to the policy.
Fiasp was added to the first-line insulin products.
Admelog was added to the policy.
The Insulin Lispro branded generic was added to the policy.
Merilog was added to the policy as a non-preferred product.
A criterion was added requiring that concentrated insulin products not be used in an external insulin pump.
Kirsty was added to the policy as a non-preferred product.
Preferred insulin products were updated to Kirsty and insulin lispro products, while Novolog and Fiasp products were moved to non-preferred status.
A criterion was added requiring that Humulin R U-500 not be used in an external insulin pump.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.